{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:00Z","timestamp":1792180620173,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Lassen Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51600-0","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:07:40Z","timestamp":1777712860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease"],"prefix":"10.1038","volume":"16","author":[{"given":"David J.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Swaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadmus","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Toni","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chidester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Witherden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hershoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarya","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Strauwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona Z.","family":"Silkiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Oester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Garrido-Hermosilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsan","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don O.","family":"Kikkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"51600_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cytogfr.2015.07.015","volume":"26","author":"CM Johnstone","year":"2015","unstructured":"Johnstone, C. M. et al. Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer. Cytokine Growth Factor Rev. 26, 489\u2013498. https:\/\/doi.org\/10.1016\/j.cytogfr.2015.07.015 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"51600_CR2","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20220160","author":"SA Cook","year":"2023","unstructured":"Cook, S. A. Understanding interleukin 11 as a disease gene and therapeutic target. Biochem. J. https:\/\/doi.org\/10.1042\/BCJ20220160 (2023). 480,1987\u20132008.","journal-title":"Biochem. J."},{"key":"51600_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-041818-011649","volume":"71","author":"SA Cook","year":"2020","unstructured":"Cook, S. A. & Schafer, S. Hiding in plain sight: Interleukin 11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation. Ann. Rev. Med. 71, 263\u2013276. https:\/\/doi.org\/10.1146\/annurev-med-041818-011649 (2020).","journal-title":"Ann. Rev. Med."},{"key":"51600_CR4","doi-asserted-by":"publisher","unstructured":"Myzithras, M. et al. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK\/PD modeling for an anti-IL-11 antibody therapeutic. mAbs 14, e2104153. https:\/\/doi.org\/10.1080\/19420862.2022.2104153 (2022).","DOI":"10.1080\/19420862.2022.2104153"},{"key":"51600_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125326","author":"Y Geng","year":"2019","unstructured":"Geng, Y. et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.125326 (2019).","journal-title":"JCI Insight"},{"key":"51600_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","volume":"178","author":"CS Smillie","year":"2019","unstructured":"Smillie, C. S. et al. Intra- and Inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714\u2013730. https:\/\/doi.org\/10.1016\/j.cell.2019.06.029 (2019).","journal-title":"Cell"},{"key":"51600_CR7","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1093\/rheumatology\/keab168","volume":"60","author":"E Adami","year":"2021","unstructured":"Adami, E. et al. IL11 is elevated in systemic sclerosis and IL11dependent ERK signalling underlies TGF\u03b2-mediated activation of dermal fibroblasts. Rheumatology 60, 5820\u20135826. https:\/\/doi.org\/10.1093\/rheumatology\/keab168 (2021).","journal-title":"Rheumatology"},{"key":"51600_CR8","doi-asserted-by":"publisher","first-page":"846106","DOI":"10.3389\/fendo.2022.846106","volume":"13","author":"P Wu","year":"2022","unstructured":"Wu, P. et al. IL-11 is elevated and drives the profibrotic phenotype transition of orbital fibroblasts in thyroid associated ophthalmopathy. Front. Endocrinol. 13, 846106. https:\/\/doi.org\/10.3389\/fendo.2022.846106 (2022).","journal-title":"Front. Endocrinol."},{"key":"51600_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1237","author":"B Ng","year":"2019","unstructured":"Ng, B. et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci. Trans. Med. 11, eaaw1237. https:\/\/doi.org\/10.1126\/scitranslmed.aaw1237 (2019)","journal-title":"Sci. Trans. Med."},{"key":"51600_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1053\/j.gastro.2019.05.002","volume":"157","author":"AA Widjaja","year":"2019","unstructured":"Widjaja, A. A. et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology 157, 777\u2013792. https:\/\/doi.org\/10.1053\/j.gastro.2019.05.002 (2019).","journal-title":"Gastroenterology"},{"key":"51600_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ajh\/hpz194","volume":"33","author":"C Menendez-Castro","year":"2020","unstructured":"Menendez-Castro, C. et al. Correlations between Interleukin-11 expression and hypertensive kidney injury in a rat model of renovascular hypertension. Am. J. Hypertens. 33, 331\u2013340. https:\/\/doi.org\/10.1093\/ajh\/hpz194 (2020).","journal-title":"Am. J. Hypertens."},{"key":"51600_CR12","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s41467-021-22450-3","volume":"12","author":"T Nishina","year":"2021","unstructured":"Nishina, T. et al. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat. Commun. 12, 2281. https:\/\/doi.org\/10.1038\/s41467-021-22450-3 (2021).","journal-title":"Nat. Commun."},{"key":"51600_CR13","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1016\/j.celrep.2019.05.077","volume":"27","author":"A Strikoudis","year":"2019","unstructured":"Strikoudis, A. et al. Modeling of fibrotic lung disease using 3D organoids derived from human pluripotent stem cells. Cell. Rep. 27, 3709\u20133723. https:\/\/doi.org\/10.1016\/j.celrep.2019.05.077 (2019).","journal-title":"Cell. Rep."},{"key":"51600_CR14","doi-asserted-by":"publisher","unstructured":"Rashad, R. et al. Thyroid eye disease. Life (2084). https:\/\/doi.org\/10.3390\/life12122084 (2022).","DOI":"10.3390\/life12122084"},{"key":"51600_CR15","doi-asserted-by":"publisher","first-page":"e220303","DOI":"10.1530\/EC-22-0303","volume":"11","author":"J Supronik","year":"2022","unstructured":"Supronik, J. et al. Rituximab in the treatment of Graves\u2019 orbitopathy: Latest updates and perspectives. Endocr. Connect. 11, e220303. https:\/\/doi.org\/10.1530\/EC-22-0303 (2022).","journal-title":"Endocr. Connect."},{"key":"51600_CR16","doi-asserted-by":"publisher","first-page":"101620","DOI":"10.1016\/j.beem.2022.101620","volume":"37","author":"ACH Lee","year":"2023","unstructured":"Lee, A. C. H. & Kahaly, G. Pathophysiology of thyroid associated orbitopathy. Best Pract. Res. Clin. Endocrinol. Metabolism. 37, 101620. https:\/\/doi.org\/10.1016\/j.beem.2022.101620 (2023).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabolism"},{"key":"51600_CR17","unstructured":"https:\/\/rarediseases.org\/rare-diseases\/thyroid-eye-disease"},{"key":"51600_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11154-021-09685-7","volume":"23","author":"E Kardalas","year":"2022","unstructured":"Kardalas, E. et al. The role of transforming growth factor beta in thyroid autoimmunity: Current knowledge and future perspectives. Rev. Endocr. Metab. Disord. 23, 431\u2013447. https:\/\/doi.org\/10.1007\/s11154-021-09685-7 (2022).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"51600_CR19","doi-asserted-by":"publisher","first-page":"607114","DOI":"10.3389\/fendo.2020.607144","volume":"11","author":"GE Lee","year":"2021","unstructured":"Lee, G. E. et al. Role of proprotein convertase subtilisin\/kexin type 9 in the pathogenesis of graves\u2019 orbitopathy in orbital fibroblasts. Front. Endocrinol. 11, 607114. https:\/\/doi.org\/10.3389\/fendo.2020.607144 (2021).","journal-title":"Front. Endocrinol."},{"key":"51600_CR20","doi-asserted-by":"publisher","first-page":"1537365","DOI":"10.3389\/fimmu.2025.1537365","volume":"16","author":"Z Peng","year":"2025","unstructured":"Peng, Z. et al. PDK-2-enhanced glycolysis aggravates fibrosis via IL-11 signaling pathway in Graves\u2019 orbitopathy. Front. Immunol. 16, 1537365. https:\/\/doi.org\/10.3389\/fimmu.2025.1537365 (2025).","journal-title":"Front. Immunol."},{"key":"51600_CR21","doi-asserted-by":"publisher","first-page":"36197","DOI":"10.1074\/jbc.m004648200","volume":"46","author":"VA Barton","year":"2000","unstructured":"Barton, V. A. et al. Interleukin-11 signals through the formation of a hexameric receptor complex. J. Biol. Chem. 46, 36197\u201336203. https:\/\/doi.org\/10.1074\/jbc.m004648200 (2000).","journal-title":"J. Biol. Chem."},{"key":"51600_CR22","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1074\/jbc.ra119.012351","volume":"295","author":"RD Metcalfe","year":"2020","unstructured":"Metcalfe, R. D. et al. The structure of the extracellular domains of human interleukin 11\u03b1 receptor reveals mechanisms of cytokine engagement. J. Biol. Chem. 295, 8285\u20138301. https:\/\/doi.org\/10.1074\/jbc.ra119.012351 (2020).","journal-title":"J. Biol. Chem."},{"key":"51600_CR23","doi-asserted-by":"publisher","first-page":"e250080","DOI":"10.1530\/JME-25-0080","volume":"76","author":"HJ Yoon","year":"2026","unstructured":"Yoon, H. J. et al. Therapeutic effect of IL-11 inhibition in the pathogenesis of thyroid eye disease. J. Mol. Endocrinol. 76, e250080. https:\/\/doi.org\/10.1530\/JME-25-0080 (2026).","journal-title":"J. Mol. Endocrinol."},{"key":"51600_CR24","doi-asserted-by":"publisher","first-page":"14882","DOI":"10.3390\/ijms241914882","volume":"24","author":"H Werner","year":"2023","unstructured":"Werner, H. The IGF1 signaling pathway: From basic concepts to therapeutic opportunities. Int. J. Mol. Sci. 24, 14882. https:\/\/doi.org\/10.3390\/ijms241914882 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"51600_CR25","unstructured":"Horlick, R. A., Jun, H. T. & King, D. J. Anti-interleukin-11 receptor subunit alpha (IL-11R) antibodies. U.S. Patent US12129303 (2024)."},{"key":"51600_CR26","doi-asserted-by":"publisher","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","volume":"107","author":"CC Krieger","year":"2022","unstructured":"Krieger, C. C. et al. Inhibition of TSH\/IGF-1 receptor crosstalk by Teprotumumab as a treatment modality of thyroid eye disease. J. Clin. Endocrinol. Metab. 107, e1653\u2013e1660. https:\/\/doi.org\/10.1210\/clinem\/dgab824 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"51600_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000511538","volume":"9","author":"S Neuman","year":"2020","unstructured":"Neuman, S. et al. Targeting TSH and IGF-1 receptors to treat thyroid eye disease. Eur. Thyroid J. 9, 59\u201365. https:\/\/doi.org\/10.1159\/000511538 (2020).","journal-title":"Eur. Thyroid J."},{"key":"51600_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1530\/JOE-11-0488","volume":"213","author":"A Antonelli","year":"2012","unstructured":"Antonelli, A. et al. \u03b2 (CCL2) and \u03b1 (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-\u03b1 agonists in Graves\u2019 ophthalmopathy. J. Endocrinol. 213, 183\u2013191. https:\/\/doi.org\/10.1530\/JOE-11-0488 (2012).","journal-title":"J. Endocrinol."},{"key":"51600_CR29","doi-asserted-by":"publisher","first-page":"1544436","DOI":"10.3389\/fopht.2025.1544436","volume":"14","author":"J Murdock","year":"2025","unstructured":"Murdock, J. et al. The role of IL-6 in thyroid eye disease: An update on emerging treatments. Front. Ophthalmol. 14, 1544436. https:\/\/doi.org\/10.3389\/fopht.2025.1544436 (2025).","journal-title":"Front. Ophthalmol."},{"key":"51600_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1167\/iovs.66.3.33","volume":"66","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Orbital clinicopathological differences in thyroid eye disease: An analysis of cytokines with histopathological and clinical correlation. Invest. Ophthalmol. Vis. Sci. 66, 33. https:\/\/doi.org\/10.1167\/iovs.66.3.33 (2025).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"51600_CR31","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1096\/fj.202001045rr","volume":"34","author":"B Ng","year":"2020","unstructured":"Ng, B. et al. Fibroblast-specific IL11 signaling drives chronic inflammation in murine fibrotic lung disease. FASEB J. 34, 11802\u201311805. https:\/\/doi.org\/10.1096\/fj.202001045rr (2020).","journal-title":"FASEB J."},{"key":"51600_CR32","doi-asserted-by":"publisher","first-page":"e4037","DOI":"10.1210\/clinem\/dgac415","volume":"107","author":"R Fernando","year":"2022","unstructured":"Fernando, R. & Smith, T. J. Teprotumumab divergently alters fibrocyte gene expression: Implications for thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 107, e4037\u2013e4047. https:\/\/doi.org\/10.1210\/clinem\/dgac415 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"51600_CR33","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.celrep.2016.01.053","volume":"14","author":"J Lokau","year":"2016","unstructured":"Lokau, J. et al. Proteolytic cleavage governs interleukin-11 trans-signaling. Cell. Rep. 14, 1761\u20131773. https:\/\/doi.org\/10.1016\/j.celrep.2016.01.053 (2016).","journal-title":"Cell. Rep."},{"issue":"11 Pt B","key":"51600_CR34","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.bbamcr.2017.06.008","volume":"1864","author":"J Lokau","year":"2017","unstructured":"Lokau, J. et al. Proteolytic control of interleukin-11 and interleukin-6 biology. Biochim. Biophys. Acta Mol. Cell. Res. 1864 (11 Pt B), 2105\u20132117. https:\/\/doi.org\/10.1016\/j.bbamcr.2017.06.008 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"51600_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6750-12-8","volume":"12","author":"H Dams-Kozlowska","year":"2012","unstructured":"Dams-Kozlowska, H. et al. A designer hyper interleukin 11 (H11) is a biologically active cytokine. BMC Biotechnol. 12, 8. https:\/\/doi.org\/10.1186\/1472-6750-12-8 (2012).","journal-title":"BMC Biotechnol."},{"key":"51600_CR36","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena, L. et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur. J. Endocrinol. 185, G43\u2013G67. https:\/\/doi.org\/10.1530\/eje-21-0479 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"51600_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/nejmoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Eng. J. Med. 382, 341\u2013352. https:\/\/doi.org\/10.1056\/nejmoa1910434 (2020).","journal-title":"N Eng. J. Med."},{"key":"51600_CR38","unstructured":"Briceno, C. A. et al. Primary results of the phase 3 SatraGO-1 and SatraGO-2 trials: Efficacy and safety of satralizumab in thyroid eye disease. Presented at American Society of Ophthalmic, Plastic and Reconstructive Surgery, Oct. 16-17th. (2025). https:\/\/www.asoprs.org\/fall-scientific-symposium#abstract 2025."},{"key":"51600_CR39","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.4049\/jimmunol.157.4.1705","volume":"157","author":"CA Redlich","year":"1996","unstructured":"Redlich, C. A. et al. IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J. Immunol. 157, 1705\u20131710. https:\/\/doi.org\/10.4049\/jimmunol.157.4.1705 (1996).","journal-title":"J. Immunol."},{"key":"51600_CR40","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.4049\/jimmunol.157.8.3627","volume":"157","author":"WL Trepicchio","year":"1996","unstructured":"Trepicchio, W. L. et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. 157, 3627\u20133634. https:\/\/doi.org\/10.4049\/jimmunol.157.8.3627 (1996).","journal-title":"J. Immunol."},{"key":"51600_CR41","doi-asserted-by":"publisher","first-page":"8900","DOI":"10.3390\/ijms23168900","volume":"23","author":"AA Widjaja","year":"2022","unstructured":"Widjaja, A. A. et al. IL11 stimulates IL33 expression and proinflammatory fibroblast activation across tissues. Int. J. Mol. Sci. 23, 8900. https:\/\/doi.org\/10.3390\/ijms23168900 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"51600_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","volume":"552","author":"S Schafer","year":"2017","unstructured":"Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110\u2013115 (2017). http:\/\/www.nature.com\/doifinder\/10.1038\/nature24676","journal-title":"Nature"},{"key":"51600_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/cei\/uxad108","volume":"214","author":"S O\u2019Reilly","year":"2023","unstructured":"O\u2019Reilly, S. Interleukin-11 and its eminent role in tissue fibrosis: A possible therapeutic target. Clin. Exp. Immunol. 214, 154\u2013161. https:\/\/doi.org\/10.1093\/cei\/uxad108 (2023).","journal-title":"Clin. Exp. Immunol."},{"key":"51600_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2249.2012.04634.x","volume":"171","author":"AJ Naylor","year":"2013","unstructured":"Naylor, A. J., Filer, A. & Buckley, C. D. The role of stromal cells in the persistence of chronic inflammation. Cin. Exp. Immunol. 171, 30\u201335. https:\/\/doi.org\/10.1111\/j.1365-2249.2012.04634.x (2013).","journal-title":"Cin Exp. Immunol."},{"key":"51600_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1293883","author":"Y Tan","year":"2024","unstructured":"Tan, Y. et al. IL-11 mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGF\u03b2. Front. Immunol. 15, 1293883. https:\/\/doi.org\/10.3389\/fimmu.2024.1293883 (2024).","journal-title":"Front. Immunol."},{"key":"51600_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/rheumato4040013","volume":"4","author":"CM McFalls","year":"2024","unstructured":"McFalls, C. M. et al. IL-11 expression in systemic sclerosis is dependent on caspase-1 activity but does not increase collagen deposition. Rheumato 4, 163\u2013175. https:\/\/doi.org\/10.3390\/rheumato4040013 (2024).","journal-title":"Rheumato"},{"key":"51600_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.exer.2012.11.014","volume":"107","author":"P Zhao","year":"2013","unstructured":"Zhao, P. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Exp. Eye Res. 107, 65\u201373. https:\/\/doi.org\/10.1016\/j.exer.2012.11.014 (2013).","journal-title":"Exp. Eye Res."},{"key":"51600_CR48","first-page":"P29","volume":"110","author":"P Rodien","year":"2025","unstructured":"Rodien, P. et al. THRIVE-2 phase 3 trial of Veligrotug (VRDN-001) in chronic thyroid eye disease (TED): Efficacy and safety at 15 weeks. Endocrin.  Abstr 110, P29 (2025). https:\/\/www.endocrine-abstracts.org\/ea\/0110\/ea0110p29","journal-title":"Abstr"},{"key":"51600_CR49","doi-asserted-by":"publisher","first-page":"1544436","DOI":"10.3389\/fopht.2025.1544436","volume":"5","author":"J Murdoch","year":"2025","unstructured":"Murdoch, J. et al. The role of Il-6 in thyroid eye disease: An update on emerging treatments. Front. Ophthalmol. 5, 1544436. https:\/\/doi.org\/10.3389\/fopht.2025.1544436 (2025).","journal-title":"Front. Ophthalmol."},{"key":"51600_CR50","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41598-025-30716-9","volume":"16","author":"W Hua","year":"2026","unstructured":"Hua, W. et al. Transcriptome analysis of orbital tissue in thyroid eye disease uncovers key pathogenic mediators. Sci. Rep. 16, 1058. https:\/\/doi.org\/10.1038\/s41598-025-30716-9 (2026).","journal-title":"Sci. Rep."},{"key":"51600_CR51","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1055\/a-2737-3576","volume":"242","author":"I Neumann","year":"2025","unstructured":"Neumann, I. et al. Assessing the role of tocilizumab in the treatment of thyroid eye disease; A retrospective single centre analysis. Klin. Monbl Augenheilkd. 242, 1200\u20131210. https:\/\/doi.org\/10.1055\/a-2737-3576 (2025).","journal-title":"Klin. Monbl Augenheilkd"},{"key":"51600_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras, J. V. et al. Efficacy of tocilizumab in patinets with moderate to severe corticosteroid resistant graves orbitopathy: A randomized clinical trial. Am. J. Ophthamol. 195, 181\u2013190. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038 (2018).","journal-title":"Am. J. Ophthamol"},{"key":"51600_CR53","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell. Biol. 25, 958\u2013978 (2024). https:\/\/www.nature.com\/articles\/s41580-024-00727-x","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"51600_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-024-07701-9","volume":"632","author":"AA Widjaja","year":"2024","unstructured":"Widjaja, A. A. et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature 632, 157\u2013165 (2024). https:\/\/www.nature.com\/articles\/s41586-024-07701-9","journal-title":"Nature"},{"key":"51600_CR55","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1038\/s41598-021-83991-7","volume":"11","author":"A Alberro","year":"2021","unstructured":"Alberro, A. Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency. Sci. Rep. 11, 4358 (2021). https:\/\/www.nature.com\/articles\/s41598-021-83991-7","journal-title":"Sci. Rep."},{"key":"51600_CR56","doi-asserted-by":"publisher","first-page":"300","DOI":"10.21037\/jtd-22-876","volume":"15","author":"T Arai","year":"2023","unstructured":"Arai, T. et al. Interleukin-11 in idiopathic pulmonary fibrosis: Predictive value of prognosis and acute exacerbation. J. Thorac. Dis. 15, 300\u2013310 (2023). https:\/\/jtd.amegroups.org\/article\/view\/71467\/html","journal-title":"J. Thorac. Dis."},{"key":"51600_CR57","first-page":"A2317","volume":"205","author":"M Hohmann","year":"2022","unstructured":"Hohmann, M. et al. Interleukin-11 perpetuates a vicious cycle of lung macrophage and mesenchymal cell activation in IPF. Am. J. Respir Crit. Care Med. 205, A2317 (2022). https:\/\/www.atsjournals.org\/doi\/abs\/10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A2317","journal-title":"Am. J. Respir Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51600-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:16:34Z","timestamp":1783059394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51600"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51600-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DJK, JSS, CR, HTJ, YV, SG, CC, MC, EE, DW, HH, AK, AS and MF are employees or former employees of Lassen Therapeutics. DOK is a consultant for Lassen, Amgen, Viridian, Ethyreal Bio, Crinetics,\u00a0and Argenx. AGH is a consultant for Horizon-Amgen, Viridian, Immunovant, Roche, Argenx, Kriya, Thyroscope, and AJL Ophthalmic. ALK is a consultant for Amgen, Viridian, Immunovant, Genentech\/Roche, Kriya, Lassen, Tourmaline Bio, Acelyrin, Argenx, Ethyreal Bio, and performs contracted research for Amgen, Lassen, Viridian, Kriya, and Sling. RZS is a consultant for Lassen, Argenx and Tourmaline Bio. MM and AO have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20361"}}